European Heart Journal Advance Access originally published online on March 28, 2006
European Heart Journal 2006 27(9):1010-1012; doi:10.1093/eurheartj/ehi851
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents
Unità di Ematologia e Trombosi, Ospedale San Paolo—Università di Milano, Via di Rudinì 8, 20142 Milano, Italy
* Corresponding author. Tel/fax: +39 0250323095. E-mail address: marco.cattaneo@unimi.it
This editorial refers to ‘Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin’
by S. Husted et al., on page 1038
| The first 150 words of the full text of this article appear below. |
Adenosine-5'-diphosphate (ADP) plays a key role in platelet function, because, although ADP itself is a weak platelet agonist, when secreted from the platelet dense granules where it is stored, it amplifies the platelet responses induced by other platelet agonists.1 The transduction of the ADP signal involves both a transient rise in free cytoplasmic calcium mediated by the Gq-coupled P2Y1 receptor, and inhibition of adenylyl cyclase mediated by the Gi-coupled P2Y12 receptor. Concomitant activation of both the Gq and Gi pathways by ADP is necessary to elicit normal ADP-induced platelet aggregation. Activation of the Gq pathway through P2Y1 leads to platelet shape change and rapidly reversible aggregation, whereas the activation of the Gi pathway through P2Y12 elicits a slow progressive and sustained platelet aggregation not preceded by shape change. In addition to its role in ADP-induced platelet aggregation, P2Y12 mediates the potentiation of platelet secretion induced by strong agonists
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
- Steen Husted, Håkan Emanuelsson, Stan Heptinstall, Per Morten Sandset, Mark Wickens, and Gary Peters
EHJ 2006 27: 1038-1047.[Abstract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  J.-P. Collet and G. Montalescot Review: Platelet Function Testing and Implications for Clinical Practice Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2009; 14(3): 157 - 169. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Van de Werf New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? Eur. Heart J., July 2, 2009; 30(14): 1695 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Newsome, R. S. Weller, J. C. Gerancher, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: II. Perioperative Considerations and Management Anesth. Analg., August 1, 2008; 107(2): 570 - 590. [Abstract] [Full Text] [PDF]
|
|